Principal Scientist, Discovery Toxicology
Bristol Myers Squibb
Summary
We are seeking an innovative scientist to join the Discovery Toxicology laboratory at BMS San Diego. The Discovery Toxicology team supports the early-stage discovery of pharmaceuticals, including early risk assessment, mechanistic investigation, and risk mitigation from initial target identification to candidate nomination.
Job description
The Principal Scientist will serve as an integral member of the Discovery Toxicology team, manage oversight of laboratory operations, and conduct experiments to support the progression of assets across modalities (e.g., small molecule, targeted protein degraders, antibody-drug conjugates, oligonucleotides, peptides, etc.) within the discovery portfolio.
A key area of research will include establishment and conduct of complex in vitro model experiments (e.g., gastrointestinal 3D tissues) for toxicology-related contexts of use including tissue culture and application of a variety of molecular biology and imaging techniques for analysis.
Key Responsibilities
- Maintain Biological Assessment of Risk compliance to enable continued use of all current and new cell types maintained within the laboratory
- Serve as the safety representative for the Discovery Toxicology laboratory at the San Diego site and maintain laboratory and team member compliance with Environmental Health and Safety policies
- Act as a mentor for team members with respect to laboratory techniques
- Design, execute, troubleshoot, and interpret in vitro cell culture and molecular biology experiments
- Conduct, evaluate, and interpret primary cell-based and/or iPSC-based complex in vitro models
- Apply analytical techniques such as ELISA, PCR, CRISPR, biochemical assays, immunofluorescence, Jess, flow cytometry, etc., for the functional evaluation of in vitro experiments
- Author internal reports, experimental results, posters, and/or manuscripts associated with exploratory/investigative activities in scientific journals or external conferences and present research internally
- Develop and maintain clear assay protocols and data documentation to facilitate method sharing among scientists in Discovery Toxicology
- Work collaboratively with functional experts across the organization to successfully execute projects
Requirements
- Master's Degree with 6+ years or PhD with 4+ years experience in industry or relevant academic discipline (e.g., Toxicology, Pharmacology, Biomedical Engineering, Immunology, Biology, etc.)
- General understanding of drug discovery and development
- Advanced experience in primary cell culture
- Proficient mammalian cell culture skills
- Expertise in molecular biology techniques and assay development (e.g., ELISA, Jess, flow cytometry, PCR, gene editing, imaging, etc.)
- Education/background in toxicology, cell biology, biomedical engineering, or a related field
- Ability to work in a collaborative team environment
- Advanced organizational, written and verbal communication skills
Benefits
- Medical, Dental & Vision
- Life & Disability Insurance
- Retirement Benefits
- Flexible Time Off
- 11 Paid Holidays
- Paid Sick Leave
- Volunteer Days
- Global Shutdown
- Wellbeing Support
Company overview
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Founded in 1887 and headquartered in Princeton, New Jersey, the company operates with a unique BioPharma strategy that combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a biotech firm. BMS focuses on transformative therapies in key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and fibrosis. The company has built a sustainable pipeline of potential therapies and leverages translational medicine and data analytics to deliver the right medicine to the right patient at the right time. With over 10,000 employees worldwide, Bristol Myers Squibb maintains a strong commitment to scientific excellence, patient-centric innovation, and global health equity through its foundation. The company's portfolio includes groundbreaking treatments such as Opdivo (nivolumab) for cancer, Eliquis (apixaban) for cardiovascular conditions, and Orencia (abatacept) for autoimmune diseases, among others.